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Bacterial culture for diagnosing pertussis infection has high specificity but poor sensitivity and is slow.
Highly sensitive real-time PCR assays and single-serum pertussis serology have been developed to overcome
these limitations, but there are few data available on the relative sensitivities and specificities of such assays
for pertussis diagnosis. Using data on 195 participants (>7 years old) from an epidemiological study, we
assessed the sensitivity, specificity, and performance (Youden index) for pertussis diagnosis of the pertussis
toxin enzyme-linked immunosorbent assay (using single and paired serology) and of real-time PCR assays
(using the IS481 and ptxA-Pr targets). All available diagnostic information (clinical and laboratory) was pooled
to serve as the gold standard. Single serology was the most efficient diagnostic test (Youden index, 0.57 to 0.58),
with relatively high sensitivity (>64%) and high specificity (>90%), independent of the cutoff level. IS481 PCR
performance was superior to that of ptxA-Pr PCR, and it was the second-most-efficient tool (Youden index,
0.30). Performing both ptxA-Pr and IS481 PCRs did not improve diagnostic performance. The greatest test
efficiency (Youden index, 0.69 to 0.74) was achieved when single-serum serology was used in combination with
IS481 or ptxA-Pr PCR or paired serology. Combining single serology with one PCR or paired serology increased
the sensitivity with an associated limited decrease in specificity. The most specific tests for diagnosis of
pertussis were single serology and ptxA-Pr PCR, and the most sensitive diagnostic tool was the combination of
IS481 PCR with single serology.
Currently there is no satisfactory gold standard technique
for laboratory confirmation of a pertussis infection. Although
culture is highly specific, sensitivity is low and declines with the
duration of illness, and the method may take up to 7 days to
provide a result. Using culture alone to diagnose pertussis is
likely to lead to underreporting of pertussis cases (8). Serolog-
ical assays, using one or two serum samples, have been devel-
oped to improve the sensitivity of the pertussis diagnosis, but
they have a lower specificity than culture (3, 9, 20, 25). PCR
techniques were developed to overcome these limitations, but
despite a consensus meeting in 2005 (24), these techniques still
require further standardization and optimization. To date
there are few reports (8) in which the sensitivities and speci-
ficities of these different techniques are compared using a
population exposed to pertussis.
The objective of this study was to compare the sensitivities
and specificities of the current most widely used techniques to
diagnose pertussis in exposed populations, namely, two PCR
methods (IS481 and ptxA-Pr targets) and single and paired
serology for detection of antipertussis toxin (PT) antibodies in
the serum of the patients using enzyme-linked immunosorbent
assay (ELISA) with two different cutoffs (two- or fourfold
change for paired serology and 100 or 125 ELISA units
[EU]/ml for single serology).
MATERIALS AND METHODS
Patients and specimens. We used data obtained in the course of a recent
prospective multicenter epidemiologic study (27). This study included 404 house-
hold contacts of 94 young infants (6 months of age) with laboratory-confirmed
pertussis. All contacts were interviewed face-to-face using a standard question-
naire to obtain relevant demographic and clinical data, particularly the presence
and duration of symptoms of cold or cough during the month prior to their
inclusion. They also provided nasopharyngeal aspirates or, in a few centers, swab
samples for culture and/or PCR detection of Bordetella pertussis and an acute
blood sample for detection of anti-PT immunoglobulin G (IgG). One month
later, data on the presence of cough and cold-like symptoms and a convalescent-
phase blood sample were collected from participating contacts. All nasopharyn-
geal aspirates, swabs, and sera were sent to our laboratory for analysis with
real-time PCR (using the IS481 target or the ptxA-Pr target) and measurement
of anti-PT IgG by ELISA.
Culture and analysis of isolates. Culture was performed in only a few partic-
ipating centers, resulting in five isolates from France, three from Germany, and
five from the United States. Isolates were analyzed by pulsed-field gel electro-
phoresis (PFGE) and genotyping (7) and expression of bacterial toxins and
adhesins analyzed using specific poly- and monoclonal antibodies (16, 22).
PCR. (i) Detection of B. pertussis by real-time PCR targeting the pertussis
toxin promoter (ptxA-Pr) using hybridization probes. (a) Oligonucleotide prim-
ers and hybridization probes. Oligonucleotide primers were adapted from the
work of Grimprel et al. (13) and manufactured by TibMolBiol (Berlin, Ger-
many). A pair of fluorescence-labeled hybridization probes (TibMolBiol), PT2-
FLU (5-CCT CGA TTC TTC CGT ACA TCC CGC TAC T-3 fluorescein) and
PT2-LCR640 (5 LCred640-AAT CCA ACA CGG CAT GAA CGC TCC
TTC-3 phosphate group) were designed and used for the real-time detection of
the ptxA-Pr-specific PCR product. A third probe, ICPT-LCR (5 LCred705-TGA
CTG ACA TCA GGC TTG CGC ATT GCT A-3 phosphate group), was
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designed for the detection of the specific internal-control DNA constructed for
this real-time PCR assay.
(b) Internal control. PCR inhibition was assessed by the addition of 4 fg of our
specific internal control DNA (ICD-PT) to each sample tested, which was de-
tected in duplex format. The strategy used to construct the internal control DNA
(ICD) is the overlap extension technique (15), which allows construction of an
ICD with the same primer binding sequences as the target DNA and containing
a nontarget nucleic acid sequence (chimeric DNA). The constructed ICD is
shorter (152 bp) than a natural PCR product and is inserted in the pCR4Blunt-
TOPO plasmid (Invitrogen, California) to provide an unlimited amount of ICD.
Furthermore, a specific probe (labeled with LCred705) could be designed as an
ICD-PT containing chimeric DNA. The use of the same primers is an advantage,
since multiple sets of primers might interfere with the amplification of one or
both of the target genes.
The inclusion of 4 fg ICD-PT in the PCR mixture did not affect the sensitivity
of the PCR for the detection of a ptxA-Pr-specific PCR product and allowed
correct detection of PCR failure.
(c) ptxA-Pr PCR amplification. PCR amplification was performed using a
real-time PCR system (LightCycler; Roche). The 20-l reaction mixture volume,
in a glass capillary tube, contained 4 l FastStart reaction mix hybridization
probes (a component of the FastStart DNA MasterPLUS hybridization probe kit;
Roche Diagnostics), 0.4 l dimethyl sulfoxide, 1 U uracil-DNA glycosylase, 0.5
M (each) primers PT-1 and PT-2, 0.2 M (each) probes PT2-LCR640 and
ICPT-LCR, and 0.4 M probe PT2-FLU.
Reaction conditions were 10 min at 95°C, followed by 50 cycles of 5 s at 95°C,
5 s at 66°C, and 8 s at 72°C. The fluorescence increase was measured during the
annealing step at 66°C. A readout of LC-Red 640 values (B. pertussis-specific
product) was performed using channel F2/back-F1 software, and a readout of
LC-Red705 values (internal control DNA-specific product) was performed using
channel F3/back-F2 software.
(d) Analytical sensitivity and specificity. A detection limit between 50 fg
(equivalent to 10 CFU) and 5 fg (equivalent to 1 CFU) of B. pertussis template
DNA was observed. No detection of the seven other Bordetella species, nor of
non-Bordetella respiratory organisms, i.e., the Alcaligenaceae (Achromobacter
spp. and Alcaligenes spp.) or Moraxellaceae (Branhamella spp. and Moraxella
spp.) families or Pasteurella spp. or Neisseria spp., was observed, confirming our
previous data (13).
(ii) Detection of B. pertussis by real-time PCR targeting IS481 using hybrid-
ization probes. The real-time PCR using IS481 as the target was performed
according to the recommendations of the PCR consensus meeting (24).
Serology. Serum samples were analyzed using ELISA to quantify IgG anti-PT
antibody, as previously described (25), using purified PT from Sanofi Pasteur.
The assay cutoff was set at 20 EU/ml. Positive paired serology was defined with
different cutoffs: a two- or fourfold change (25) in anti-PT IgG titers between
acute- and convalescent-phase serum samples. Positive single serology was de-
fined as a single anti-PT IgG antibody titer of 100 or 125 EU/ml (3). Anti-PT
serology results were not used to confirm pertussis in immunized children 3
months to 2 years of age and 4 to 7 years of age, since they may be influenced
by recent pertussis vaccination.
Pertussis case definition. Contacts were classified as the following: (i) symp-
tomatic, laboratory-confirmed pertussis cases, (ii) symptomatic, epidemiologi-
cally linked pertussis cases (18a), (iii) contacts with asymptomatic or subclinical
pertussis infection, or (iv) contacts without evidence of recent pertussis infection.
Epidemiologically linked cases were defined as persons in contact with the infant
index case in the month preceding symptom onset in the index case which had an
acute cough illness lasting 2 weeks but no laboratory confirmation of pertussis.
Laboratory-confirmed “asymptomatic” or subclinical cases of pertussis met the
same criteria as laboratory-confirmed symptomatic cases but did not report any
cough or cold symptoms.
The case definition for symptomatic laboratory-confirmed cases was based on
a modification of the algorithm developed by Wendelboe et al. (27). In the
current study, a case was classified as a symptomatic laboratory-confirmed case
when symptomatic and positive by culture, IS481 PCR, ptxA-Pr PCR, single
serum (125 EU/ml), or paired serology (4-fold change in ELISA titer).
Laboratory confirmation was defined as at least one positive culture, PCR
(IS481 or ptxA-Pr), or positive single or paired serology.
Statistical analysis. To avoid bias in interpretation associated with the diffi-
culties in interpreting serology with immunized children between 3 months and
7 years of age (21 participants) and with nonimmunized infants less than 3
months old (2 participants), the main analysis was performed with the 195
participants older than 7 years of age, with complete laboratory diagnostic
information both at inclusion (ptxA-Pr PCR, IS481 PCR, and serology) and 1
month later (second serology). We first calculated the sensitivity and the speci-
ficity of each of the individual laboratory techniques including ptxA-Pr PCR,
IS481 PCR, single serology with IgG antibody titers of 125 EU/ml, and paired
serology with a fourfold change in IgG titers. For the calculation of the sensitivity
of the diagnostic test i, true-positive cases were defined as symptomatic labora-
tory-confirmed cases with positive diagnostic test i and false-negative cases were
defined as symptomatic laboratory-confirmed cases with a negative result on
diagnostic test i. For the calculation of the specificity of a diagnostic test, true-
negative cases were defined as epidemiologically linked pertussis cases, contacts
with asymptomatic or subclinical pertussis infection, or contacts without evidence
of recent pertussis infection with a negative diagnostic test i and false-positive
cases as epidemiologically linked pertussis cases, contacts with asymptomatic or
subclinical pertussis infection, or contacts without evidence of recent pertussis
infection with a positive diagnostic test i.
We then determined the sensitivities and specificities of the combinations of
different tests, including single and paired serology and PCR assays (ptxA-Pr or
IS481) with single serology to estimate the ability to diagnosis pertussis using
data collected at first presentation. Sensitivities and specificities were reported
with 95% confidence intervals and compared using the Student t test. Key
demographic and clinical characteristics of participants with and without missing
laboratory data were compared using the chi-squared test. Laboratory diagnos-
tics were ranked according to the Youden index (28), a summary measure of the
reciprocal-operating-characteristics curve, to estimate the effectiveness of the
diagnostic test. The Youden index was calculated as follows: (sensitivity 
specificity)  1. A perfect diagnostic test, i.e., a test which allows complete
separation of the diseased and healthy populations, has a Youden index of 1 (12).
Finally, we performed one sensitivity analysis, using a case definition with the
other reported cutoff for single serology (IgG antibody titers of 100 EU/ml)
and paired serology (twofold change in ELISA titers) with the same case and
noncase definitions.
RESULTS
Description of the analyzed population. Among the 404 con-
tacts included in the epidemiological study, 353 participants
provided a serological sample at the inclusion visit. Within this
group, 14 participants, of ages from 3 months to 2 years or 4 to
7 years, were excluded from the analysis. ptxA-Pr PCR and
IS481 PCR were performed on samples from 289 and 288
participants, respectively. Complete laboratory data sets were
available for 256 participants at the inclusion visit and 218
participants for both visits (Table 1). Compared with those
with complete diagnostic data, participants with missing data
were more likely to be male (52% versus 39%; P  0.02), 18
years old (52.0% versus 30.7%; P  0.0001), and symptomatic
for pertussis (72.3% versus 60.1%; P  0.03) (Table 2). Among
the 218 contacts analyzed (of whom 195 were 7 years old, 21
were 3 months old and 7 years old, and 2 were 3 months
old), 95 (of whom 82 were 7 years old) had a laboratory-
confirmed symptomatic pertussis infection, 14 (of whom 10
were 7 years old) had a symptomatic epidemiologically
linked pertussis infection, 33 (of whom 32 were 7 years old)
TABLE 1. Status of completeness for pertussis laboratory diagnosis
variables: ptxA-Pr PCR, IS481 PCR, and serology
Description No. of subjects
Complete data at inclusion visit ..................................................256
Data at second visit ..................................................................218
Missing data at second visit ..................................................... 38
Missing data at inclusion visit......................................................148
On serology................................................................................ 17
On PCR...................................................................................... 97
On both PCR and serology ..................................................... 34
Total................................................................................................404
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had an asymptomatic or subclinical pertussis infection, and 76
(of whom 71 were 7 years old) were totally free of pertussis
infection.
Analysis of isolates collected during the study. Only 13 iso-
lates were collected during the study. They were collected nine
times for index cases and four times for mothers of index cases.
These adults had all PCR- and serology-positive diagnoses. All
isolates express the characterized toxins and adhesins. Geno-
typing of the PT S1 subunit showed that they all harbored
similar ptxA1 and prn2 genes except for one U.S. isolate har-
boring a prn3 gene. We previously separated B. pertussis iso-
lates into five major PFGE groups (6, 7, 25). All 13 isolates
were included in the same PFGE group, group IV. All U.S.
and French isolates were characterized as PFGE subgroup IV
beta with one exception, which was PFGE subgroup IV
gamma, and the three German ones were either PFGE sub-
group alpha or beta.
Comparative sensitivities and specificities of real-time PCR
and serological assays for diagnosis of pertussis infection.
(i) Main analysis. The number of positive tests by type of
contact is presented in Table 3. The sensitivity and specificity
of each diagnostic assay are presented for the 195 participants
with complete data at both visits (Table 4).
Among PCR assays, the sensitivity of the ptxA-Pr PCR was
significantly lower than the sensitivity of the IS481 PCR
(15.9% versus 45.1%; P  109), whereas the specificity of the
ptxA-Pr PCR was significantly higher than that for IS481 PCR
(97.3% versus 85.0%; P  105).
Single serology was significantly more sensitive (64.6% ver-
sus 15.9%; P  109)) than paired serology and had compa-
rable specificity (92.0% versus 89.4%; P  0.19. Single serology
was also more sensitive than the IS481 PCR (64.6% versus
45.1%; P  104) and the ptxA-Pr PCR (64.6% versus 15.9%;
P  109).
Single serology was more specific than IS481 PCR (92.0%
versus 85.0%; P  0.02) but less specific than the ptxA-Pr PCR
(92.0% versus 97.3%; P  0.01).
Among all individual diagnostic assays, single serology was
the most efficient assay, with Youden indices of 0.57, compared
to 0.31 for all other assays.
As summarized by the Youden indices (Table 4), the most
efficient laboratory diagnoses for symptomatic laboratory-con-
firmed pertussis cases were the combination of single serology
with paired serology or one PCR test. The most sensitive test
was the combination of single serology with IS481 PCR, and
the most specific was the combination of single serology with
ptxA-Pr PCR.
(ii) Sensitivity analyses. Using more-sensitive cutoffs for
serology (100 and a twofold change), there were 84 cases and
111 noncases. Lowering the single-serum cutoff to 100
EU/ml or the cutoff for paired serology to a 2-fold change in
titer slightly improved efficiency of individual tests due to a
modest increase in sensitivity and a small decrease in specific-
ity; nevertheless, the results for the estimated sensitivity and
specificity of the laboratory tests were comparable to those
reported in the main analysis (Table 5). The most specific
diagnostic tests were the combination of single serology with
ptxA-Pr PCR or IS481 PCR, and the most sensitive were the
combination of single serology with paired serology or with the
IS481 PCR.
DISCUSSION
This study was performed in order to compare different
pertussis biological diagnostic techniques in current routine
use. The source data were obtained from a multicenter house-
hold study on pertussis transmission (27) in which five diag-
nostic measures were used: culture, two PCR assays with dif-
ferent DNA targets, and single and paired PT ELISAs with
two cutoffs.
Culture was not performed in all centers because of the
difficulty in isolating B. pertussis, the lack of sensitivity, and the
long delay necessary to obtain the result (8). However, it is
important to note that pursuing culture is essential in order to
TABLE 2. Description of participants according to existing missing








Total participants 148 218
Clinical symptoms
present, % (no.)
72.3 (107) 60.1 (131) 0.03
Sex distribution, % (no.) 0.02
Men 52.0 (77) 39.0 (85)
Women 48.0 (71) 61.0 (133)
Age (median), yrs 15.5 27.0
Age (2 classes), % (no.) 0.0001
Adults, 18 yrs 48.0 (71) 69.3 (151)
Children, 18 yrs 52.0 (77) 30.7 (67)
Age (4 classes), % (no.) 0.00001
10 yrs 41.2 (61) 14.2 (31)
10 yrs–18 yrs 10.8 (16) 16.5 (36)
18 yrs–50 yrs 42.6 (63) 60.1 (131)
50 yrs 5.4 (8) 9.2 (20)
Continent, % (no.) 0.89
North America 67.6 (100) 68.8 (150)
Europe 32.4 (48) 31.2 (68)
TABLE 3. Distribution of positive and negative cases with
laboratory-confirmed pertussis for participants
7 years olda




ptxA-Pr PCR 13 3
IS481 PCR 37 17
Single serology (125 EU/ml) 53 9
Paired serology (4b) 13 12
Positive pertussis test using combination of
single serology (125 EU/ml) with:
Paired serology (4) 66 12
PtxA-Pr PCR 62 12
IS481 PCR 73 23
a Subjects were contacts of infant pertussis cases with complete laboratory data
(n  195). Complete data include symptoms, serology, and PCR (IS481 and
ptx-Pr) at enrollment and symptoms and serology at follow-up visit 1 month later.
b 4, fourfold change in titer.
c Case definition: laboratory-confirmed symptomatic contact. There were 82
cases and 113 noncases.
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analyze the spatio-temporal evolution of Bordetella pertussis
according to the immunity of the human population. We ob-
served that the collected isolates were very similar to each
other (all PFGE group IV), confirming our previous results
obtained in Argentina (4), Europe (7), Japan (14), Russia (17),
and France (6, 26). We demonstrated that the PFGE group IV
subgroup gamma, first observed in Finland and more recently
in France (5, 7), is now also circulating in the United States.
Because of the long delay necessary to isolate the bacteria,
many real-time PCR assays have been developed in recent
years for routine diagnoses of pertussis. After a consensus
meeting in 2005, recommendations were published (24). It was
underlined that real-time ptxA-Pr PCR was less sensitive but
more specific than IS481 PCR (24), since IS481 PCR can
detect Bordetella holmesii species and some Bordetella bronchi-
septica and B. pertussis spp. This may not impact substantially
on test performance, since the incidence of B. holmesii respi-
ratory infections seems to be very low, as is that of B. bronchi-
septica, which infects mostly immunosuppressed individuals (2,
11). In the present study, we confirmed that ptxA-Pr real-time
PCR is less sensitive than IS481 PCR and demonstrated that
performing both ptxA-Pr and IS481 PCR does not improve
diagnostic performance. Furthermore, we did not observe any
ptxA-Pr PCR-positive case which was negative by IS481 PCR.
This observation is in contrast with that of Qin et al. (23).
Qin et al. speculate that the underperformance of IS481
compared to that of the multicopy IS may have been a result of
nonrandom genome degradation of IS481, which is considered
a nonessential genomic element, during the course of host-
pathogen interaction at a later disease stage. The difference
between the two studies may also be explained by a difference
in the study population, with the Qin study including mainly
young children (median age, 2.5 years) suspected of having
pertussis infection, whereas our study included contacts of
infant index cases (median age, 27 years) investigated at a later
stage of disease. However, even among those contacts that
were assessed when symptomatic for a short period of time, we
did not observe any ptxA-Pr PCR-positive case which was neg-
ative by IS481 PCR. Our data confirm that IS481 real-time
PCR is a useful diagnostic tool.
ELISA determinations of anti-PT antibody titers are a val-
idated and very sensitive diagnostic method which can be used
with single serum or paired (acute- and convalescent-phase)
serum samples (8). A fourfold change in the titers of anti-PT
antibodies was believed to be the most sensitive and specific
biological diagnosis (25). However, the paired serum sample
assay is impractical for routine diagnosis. For this reason, sin-
gle-sample serology has been developed and IgG cutoff values
have been determined for a number of laboratories (3, 8, 9),
and this method is now used for routine diagnosis. In the
present study, we compared single and paired serology and two
different cutoffs. Twofold changes were more sensitive but less
specific than fourfold changes. Single serology, independently
of the cutoff used, was more sensitive and more specific than
paired serology, and the agreement was poor between single
and paired serology results. We demonstrated that the perfor-
TABLE 4. Comparative sensitivities, specificities, and Youden index for diagnosis of symptomatic laboratory-confirmed pertussisa
Method of diagnosis (cutoff) % Sensitivity (95% CIc) % Specificity (95% CI) Youden index
ptxA-Pr PCR 15.9 (10.8–21.0) 97.3 (95.1–99.5) 0.13
IS481 PCR 45.1 (38.1–52.1) 85.0 (80.0–90.0) 0.30
Single serology (125 EU/ml) 64.6 (57.9–71.3) 92.0 (88.2–95.8) 0.57
Paired serology (4b) 15.9 (10.8–21.0) 89.4 (85.1–93.7) 0.05
Combination of single serology (125 EU/ml) with:
Paired serology, (4) 80.4 (74.8–86.0) 89.4 (85.1–93.7) 0.70
ptxA-Pr PCR 75.6 (69.6–81.6) 98.2 (96.3–100) 0.74
IS481 PCR 89.0 (84.6–93.4) 79.6 (73.9–85.3) 0.69
a Subjects are contacts of infant pertussis cases for whom there is complete laboratory data (n  195). Complete data include symptoms, serology, and PCR (IS481
and ptx-Pr) at enrollment and symptoms and serology at follow-up visit 1 month later.
b 4, fourfold change in titer.
c CI, confidence interval.
TABLE 5. Comparative sensitivities, specificities, and Youden index for diagnosis of symptomatic laboratory-confirmed pertussisa
Method of diagnosis (cutoff) % Sensitivity (95% CIc) % Specificity (95% CI) Youden index
ptxA-Pr PCR 15.5 (10.4–20.6) 97.3 (95.0–99.6) 0.13
IS481 PCR 44.0 (37.0–51.0) 84.7 (79.6–89.8) 0.29
Single serology (100) 67.9 (61.3–74.5) 90.1 (85.9–94.3) 0.58
Paired serology (2b) 23.8 (17.8–29.8) 83.8 (78.6–89.0) 0.08
Combination of single serology (100 EU/ml) with:
Paired serology (2) 85.7 (80.8–90.6) 75.7 (69.7–81.7) 0.61
PtxA Pr PCR 77.4 (71.5–83.3) 87.4 (82.7–92.1) 0.65
IS481 PCR 90.5 (86.4–94.6) 77.5 (71.6–83.4) 0.68
a Subjects are contacts of infant pertussis cases for whom there is complete laboratory data (n  195). Complete data include symptoms, serology, and PCR analysis
(IS481 and ptx-Pr) at enrollment and symptoms and serology at follow-up visit 1 month later.
b 2, twofold change in titer.
c CI, confidence interval.
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mance of the combination of single serology with paired serol-
ogy did not improve the performance of single serology and
confirmed the usefulness of single serology for routine diag-
nosis of pertussis.
This study is subject to some limitations. Culture has tradi-
tionally served as an imperfect gold standard, but its poor
sensitivity limits the ability to assess the performance of other
diagnostic tests. Hence, an algorithm was developed which
incorporated diagnostic information from all available sources
(i.e., PCR, serum, and symptoms). While the use of an algo-
rithm as a pooled gold standard is superior to treating a single
imperfect diagnostic test as an absolute gold standard, using a
pooled gold standard potentially results in overestimating the
sensitivities and specificities of the individual tests included in
the pooled gold standard (21). To compare the values of the
different diagnostic tests, we presented the sensitivity, specific-
ity, and Youden index for each of the tests assessed. The
Youden index is an attractive single value for the effectiveness
of a diagnostic marker in distinguishing between diseased and
nondiseased populations. A limitation of the Youden index
stems from the fact that it gives equal weight to the sensitivity
and specificity. Depending on the setting in which the test is
used, a health care provider or researcher may want to give
greater weight to either the sensitivity or specificity of a par-
ticular diagnostic test.
All the participants included in these analyses were close
contacts of confirmed cases of pertussis infection who had a
higher probability of being exposed to B. pertussis than the
general population and therefore had a higher probability of
having a positive laboratory test.
In addition, this study design could have produced a rela-
tively large number of asymptomatic contacts with positive
laboratory tests, thus biasing the estimate of the sensitivity and
specificity of these laboratory tests compared to those for the
general population. Further research is needed to determine if
the same levels of sensitivity and specificity and the same
ranking of test efficacy are obtained with the general popula-
tion.
In conclusion, IS481 PCR and single-serum serology are
currently the most efficient diagnostic tools available for per-
tussis diagnosis for children of ages 7 years, adolescents, and
adults in contact with a pertussis case. The combination of both
assays provides the most sensitive diagnostic tool for pertussis
at the time of presentation to a health care facility. Culture will
remain valuable since it allows for the analysis of the spatio-
temporal evolution of the bacterium.
The efficiency of single serology may require future reeval-
uation, however, because of changes in pertussis vaccines (re-
placement of whole-cell vaccines with acellular ones) and new
vaccine recommendations which promote booster vaccinations
for adolescents and adults (1, 18). Acellular vaccines contain
fewer antigens than whole-cell vaccines and induce different
and larger humoral immune responses than whole-cell vac-
cines (10). The use of single serum may thus decrease with
more-widespread implementation of booster vaccinations,
since serological diagnoses can be performed only after a wait-
ing period of 2 to 3 years following a booster immunization
with a pertussis acellular vaccine (19).
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